2 completed, 2 recruiting, 1 active not recruiting, 1 enrolling by invitation. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1 |
Follow MapLight Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia ML-007C-MA - Schizophrenia | Phase 2 | Recruiting | MapLight Therapeutics | 500 | 2026-03-31 | 2026-10-15 |
| An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis ML-007C-MA - Psychosis Associated With Alzheimer's Disease | Phase 2 | Enrolling by invitation | MapLight Therapeutics | 210 | 2026-03-25 | 2026-08-07 |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis ML-007C-MA, Placebo - Psychosis Associated With Alzheimer's Disease | Phase 2 | Recruiting | MapLight Therapeutics | 300 | 2025-08-15 | 2026-09-30 |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia Placebo, ML-007C-MA BID, ML-007C-MA QD - Schizophrenia | Phase 2 | Completed | MapLight Therapeutics | 307 | 2025-06-27 | 2026-07-09 |
| ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) ML-004 (IR)/(ER) tablet - Autism Spectrum Disorder | Phase 2 | Active not recruiting | MapLight Therapeutics | 120 | 2023-06-01 | 2026-07-20 |
| ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) ML-004 (IR)/(ER) tablet, ML-004 Placebo - Autism Spectrum Disorder | Phase 2 | Completed | MapLight Therapeutics | 168 | 2022-09-13 | 2026-05-19 |
Brain Diseases (4) · Central Nervous System Diseases (4) · Mental Disorders (4) · Nervous System Diseases (4) · Psychotic Disorders (4) · Alzheimer Disease (2) · Autism Spectrum Disorder (2) · Autistic Disorder (2) · Communication (2) · Delusions (2) · Dementia (2) · Hallucinations (2) · Neurocognitive Disorders (2) · Neurodegenerative Diseases (2) · Schizophrenia (2)
Tablets (2)
United States (6) · Canada (3) · Australia (2) · Bulgaria (2) · France (2) · Argentina (1) · Chile (1) · Czechia (1) · Hungary (1) · Italy (1) · Poland (1) · Portugal (1) · Romania (1) · Serbia (1) · Slovakia (1)
2025 (1)